A World First at the Montreal Heart Institute - Discovery of a Personalized Therapy for Cardiovascular Disease

A World First at the Montreal Heart Institute - Discovery of a Personalized Therapy for Cardiovascular Disease

PR Newswire

MONTREAL January 12 2015

MONTREAL January 12 2015 /PRNewswire/ --

Important reduction in events including heart attacks and deaths in patients with the appropriate genetic background to respond to a new medication

Researchers at the Montreal Heart Institute announced today results showing that patients with cardiovascular disease and the appropriate genetic background benefit greatly from the new medication dalcetrapib with a reduction of 39% in combined clinical outcomes including heart attacks strokes unstable angina coronary revascularizations and cardiovascular deaths. These patients also benefit from a reduction in the amount of atherosclerosis (thickened walls) in their vessels. The detailed results are published in the prestigious Journal Circulation Cardiovascular Genetics. This discovery may also pave the way for a new era in cardiovascular medicine with personalized or precision drugs.

The team led by Drs Jean-Claude Tardif and Marie-Pierre Dubé performed the analysis of 5749 patients who received dalcetrapib or placebo and provided DNA in a clinical study. A strong association was discovered between the effects of dalcetrapib and a specific gene called ADCY9 (adenylate cyclase 9) on chromosome 16 particularly for a specific genetic variant (rs1967309). In patients with the genetic profile AA at rs1967309 there was a 39% reduction in the composite cardiovascular endpoint with dalcetrapib compared to placebo. Supporting evidence was also obtained from a second study which showed that patients with the favourable genetic profile also benefited from a reduction in the thickness of their carotid artery walls with dalcetrapib.

"These results will lead to a genetics-guided clinical study in patients with the appropriate genetic background to allow review by health regulatory agencies and to provide personalized therapy with dalcetrapib. It also offers great hope for precision treatments for patients with cardiovascular diseases and for curbing atherosclerosis the first cause of mortality in the world" said lead investigator Jean-Claude Tardif MD director of the Research Center at the Montreal Heart Institute and professor of medicine at the University of Montreal.

The investigators tested multiple genetic markers across the entire genome in a procedure called genome-wide association study. "We used state-of-the-art genetic and statistical techniques to demonstrate that the effect of the patient's genetic profile was only observed in those treated with dalcetrapib and not placebo. We want to provide patients with additional personalized cardiovascular therapies in the years to come for more efficacious and safer medicines" commented Marie-Pierre Dubé PhD director of the Beaulieu-Saucier Pharmacogenomics Center at the Montreal Heart Institute and professor of medicine at the University of Montreal.

Dr. Jean-Claude Tardif is available for interviews.
To read the article: http://bit.ly/1tZSSG9
To consult the Journal of the American heart Association website : http://circgenetics.ahajournals.org

Media Invitation : Wednesday January 14 2015 at 10:30 AM Auditorium Jean Parisien at the Montreal Heart Institute 5000 Bélanger streetMontréal Québec H1T 1C8 RSVP : Lise Plante 514 376-3330 ext 3898Dr Jean-Claude Tardif will present the study highlights.

Dr Jean-Claude Tardif
https://www.icm-mhi.org/en/research/researchers/493-jean-claude-tardif

Dre Marie-Pierre Dubé
https://www.icm-mhi.org/fr/recherche/chercheurs/501-marie-pierre-dube

About the Montreal Heart Institute : http://www.icm-mhi.org

About the Montreal Heart Institute Foundation
http://www.icm-mhi.org

Lise Plante MBA Communications and Marketing Director Montreal Heart Institute Foundation Phone: +1-514-376-3330 ext. 3898 [email protected] facebook.com/institutcardiologiemontreal @ICMtl

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.